Extended report: Sifalimumab an anti-interferon-α monoclonal antibody in moderate to severe systemic lupus erythematosus: a randomised double-blind placebo-controlled study

摘要

ObjectivesThe efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study () of adults with moderate to severe active systemic lupus erythematosus (SLE).